| Latest ADVENTRX PHARMACEUTICALS News Headlines |
| Date | Time | Source | |
| 12/15/2008 | 9:00AM | PRNUS | ADVENTRX Exploring Strategic Options
SAN DIEGO, Dec. 15 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates primarily for the treatment of cancer, today announced that it is exploring a range of strategic options, including... More...>> |
| 12/15/2008 | 9:00AM | PRNUS | ADVENTRX Exploring Strategic Options
SAN DIEGO, Dec. 15 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates primarily for the treatment of cancer, today announced that it is exploring a range of strategic options, including... More...>> |
| 11/06/2008 | 4:01PM | PRNUS | ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
Conference call scheduled for November 6, 2008 at 1:30 p.m. (Pacific Time); simultaneous webcast at www.adventrx.com
SAN DIEGO, Nov. 6 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates... More...>> |
| 11/04/2008 | 6:00AM | PRNUS | ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
SAN DIEGO, Nov. 4 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) today announced that Mark Erwin, Senior Vice President, Operations of ADVENTRX, is scheduled to present at the Rodman & Renshaw 10th Annual Global Healthcare Conference. Mr. Erwin is scheduled to present on Tuesday, November 11th... More...>> |
| 10/30/2008 | 6:00AM | PRNUS | ADVENTRX Pharmaceuticals to Report Third Quarter 2008 Results
Conference call scheduled for November 6, 2008 at 1:30 p.m. (Pacific); simultaneous webcast at www.adventrx.com
SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) today announced that it will host a conference call with simultaneous webcast to discuss third quarter 2008 results on... More...>> |
| 10/20/2008 | 6:00AM | PRNUS | ADVENTRX Announces Restructuring and Cost Reduction Initiatives
- CEO Resigns; Executive Team Reorganized; 27% Reduction in Force
SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) announced today that it has implemented a restructuring designed to reduce operating costs while continuing advancement towards the Company's near term goals. ADVENTRX... More...>> |
| 08/11/2008 | 4:01PM | PRNUS | ADVENTRX Pharmaceuticals Reports Second Quarter 2008 Financial Results and Business Update
Conference call scheduled for August 12, 2008 at 1:30 p.m. (Pacific Time); simultaneous webcast at www.adventrx.com
SAN DIEGO, Aug. 11 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates... More...>> |
| 08/08/2008 | 6:00AM | PRNUS | ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
Conference call scheduled for August 12, 2008 at 1:30 p.m. (Pacific); simultaneous webcast at www.adventrx.com
SAN DIEGO, Aug. 8 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) today announced that it will host a conference call with simultaneous webcast to discuss second quarter 2008 results on... More...>> |
| 07/01/2008 | 6:00AM | PRNUS | ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
SAN DIEGO, July 1 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) today announced preliminary response rate results from its discontinued Phase 3 clinical trial of ANX-510, or CoFactor, the Company's folate-based biomodulator of 5-FU (5 fluorouracil), for the treatment of first-line metastatic colorectal... More...>> |
| 06/30/2008 | 6:00AM | PRNUS | ADVENTRX Settles Dispute With Former Licensee
SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) today announced that it settled its dispute with Theragenex, LLC and its Chairman and President and Chief Executive Officer for payments aggregating $600,000, which payments the Company has received in full. The parties have agreed... More...>> |
| 06/16/2008 | 6:00AM | PRNUS | ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
SAN DIEGO, June 16 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) today provided an update with regard to overall survival from its Phase 2b clinical trial of CoFactor for the treatment of first-line metastatic colorectal cancer. Overall survival results in this study have been revised upwards slightly... More...>> |
| 06/03/2008 | 6:00AM | PRNUS | ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
SAN DIEGO, June 3 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) announced today that it presented objective response rate and available safety data from the Company's Phase 2 clinical study of ANX-510, or CoFactor(R), for the treatment of advanced breast cancer at the 2008 American Society of Clinical... More...>> |
| 05/16/2008 | 6:00AM | PRNUS | ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
- ANX-530 Demonstrates Statistically Significant Reductions in Selected Safety Observations
SAN DIEGO, May 16 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) announced today that, in a registrational bioequivalence clinical study, ANX-530 demonstrated a statistically significant reduction in general... More...>> |
| 05/13/2008 | 6:00AM | PRNUS | ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
SAN DIEGO, May 13 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) today announced that Evan M. Levine, ADVENTRX's Chief Executive Officer and President, is scheduled to present at the Rodman & Renshaw 5th Annual Global Healthcare Conference. Mr. Levine is scheduled to present on Tuesday, May 20... More...>> |
| 05/12/2008 | 6:00AM | PRNUS | ADVENTRX Pharmaceuticals Reports First Quarter 2008 Financial Results
Conference call scheduled for May 12, 2008 at 1:30 p.m. (Pacific Time); simultaneous webcast at www.adventrx.com
SAN DIEGO, May 12 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates primarily... More...>> |
| 05/05/2008 | 6:00AM | PRNUS | ADVENTRX Pharmaceuticals to Report First Quarter 2008 Results
Conference call scheduled for May 12, 2008 at 1:30 p.m. (Pacific); simultaneous webcast at http://www.adventrx.com
SAN DIEGO, May 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) today announced that it will host a conference call with simultaneous webcast to discuss first quarter 2008 results on... More...>> |
| 04/15/2008 | 6:00AM | PRNUS | ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study
ADVENTRX Presents Data at the 2008 American Association for Cancer Research Annual Meeting
SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) announced that it presented pharmacokinetic data from its registrational bioequivalence clinical study of ANX-530 (vinorelbine emulsion) at... More...>> |
| 04/09/2008 | 6:00AM | PRNUS | ADVENTRX Appoints Vice President of Manufacturing
SAN DIEGO, April 9, 2008 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) announced today that it has appointed Jose Hechavarria to the new position of vice president of manufacturing. Mr. Hechavarria will be responsible for leading the company's planned commercial manufacturing operations.
"We are... More...>> |
| 04/03/2008 | 3:00PM | PRNUS | ADVENTRX Creates Executive Vice President Position and Announces New Chief Financial Officer
SAN DIEGO, April 3, 2008 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) announced today that Mark Bagnall, a member of the Company's Board of Directors, has joined the Company as Executive Vice President, a newly created position, and Chief Financial Officer. As Executive Vice President, Mr. Bagnall... More...>> |
| 03/31/2008 | 6:00AM | PRNUS | ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests
ADVENTRX Presents Results at Keystone Symposia HIV Pathogenesis Conference
SAN DIEGO, March 31 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) announced that it presented preclinical results for ANX-201, the Company's broad-spectrum antiviral product candidate at the Keystone Symposia HIV Pathogenesis... More...>> |